SCHEMBL29733705

SCHEMBL29733705

COc1cccc(C(=O)CNC(=O)c2cccc(CN3CCN(C(=O)OC(C)(C)C)CC3)c2)c1

nearest known ligand 0.54

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 4/20 0.54
▸ KMT2A Q03164 4/20 0.54
▸ CHRM3 P20309 1/20 0.52
▸ DRD4 P21917 2/20 0.51
▸ SMN1; SMN2 Q16637 3/20 0.50
▸ KDM4E B2RXH2 3/20 0.50
▸ ALDH1A1 P00352 3/20 0.50
▸ KCNH2 Q12809 2/20 0.49
▸ LMNA P02545 4/20 0.49
▸ MAPT P10636 3/20 0.49
▸ FAAH O00519 2/20 0.48
▸ RECQL P46063 1/20 0.48
▸ HTT P42858 1/20 0.48
▸ CCR2 P41597 1/20 0.47
▸ MMP13 P45452 1/20 0.47
▸ MCHR1 Q99705 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23014383 1.00 MEN1 (0.54) MEN1KMT2ACHRM3DRD4SMN1; SMN2
SCHEMBL29733707 0.90 KDM4E (0.52) MEN1KMT2ASMN1; SMN2KDM4EALDH1A1
SCHEMBL23014291 0.90 KDM4E (0.52) MEN1KMT2ASMN1; SMN2KDM4EALDH1A1
SCHEMBL23014485 0.84 DRD4 (0.60) MEN1KMT2ACHRM3DRD4SMN1; SMN2
SCHEMBL23014313 0.83 CYP2C9 (0.66) MEN1KMT2ACHRM3DRD4SMN1; SMN2
SCHEMBL23014318 0.82 DRD4 (0.69) DRD4SMN1; SMN2LMNAMAPT
SCHEMBL8294657 0.81 GLS (0.50) MEN1KMT2ACHRM3SMN1; SMN2KDM4E
SCHEMBL1022120 0.80 GLS (0.49) MEN1KMT2ACHRM3SMN1; SMN2KDM4E
SCHEMBL1020384 0.80 MEN1 (0.53) MEN1KMT2ACHRM3SMN1; SMN2KDM4E
SCHEMBL30525131 0.80 MEN1 (0.53) MEN1KMT2ACHRM3SMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4019495-A1 NOVEL COMPOUND HAVING CANCER METASTASIS INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION FOR INHIBITING CANCER METASTASIS AND INVASION OR TREATING COLORECTAL CANCER, COMPRISING COMPOUND Cellgentek Co., Ltd (KR) 2022-06-29 — — EP disclosed
Send feedback